Previous 10 | Next 10 |
Demonstrates LENSAR Laser’s Ability to Guide Improved Astigmatic Outcomes for Patients LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for...
LENSAR, Inc. (LNSR) Q3 2021 Results Conference Call November 08, 2021 08:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nick Curtis - CEO Tom Staab - CFO Conference Call Participants Danielle Antalffy - SVB Leerink Ryan Zimmerman - BTIG Presentation Operator Good morning, a...
LENSAR (NASDAQ:LNSR): Q3 GAAP EPS of -$0.65 misses by $0.06. Revenue of $8.3M (+16.1% Y/Y) beats by $0.63M. Press Release For further details see: LENSAR EPS misses by $0.06, beats on revenue
Third Quarter 2021 Procedure Volumes Increase 23% over 2020 Levels Cash and Cash Equivalents of $32.3 Million reflect Cash Utilization of $2.2 Million in the Quarter LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical...
LENSAR, Inc. (NASDAQ: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s third quarter 2021 financial result...
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the...
LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that Nick Curtis, Chief Executive Officer will present at the...
LENSAR, Inc. (LNSR) Q2 2021 Results Earnings Conference Call August 05, 2021, 8:30 am ET Company Participants Lee Roth - Investor Relations, Senior Vice President of Investor Relations at Burns McClellan Nick Curtis - Chief Executive Officer Tom Staab - Chief Financial Officer Conference Call...
LENSAR (NASDAQ:LNSR): Q2 GAAP EPS of -$0.47 beats by $0.12. Revenue of $7.9M (+56.4% Y/Y) beats by $0.77M. Press Release For further details see: LENSAR EPS beats by $0.12, beats on revenue
Second Quarter and First Half 2021 Procedure Volumes Increase 70% and 42% over 2020 Levels Cash and Cash Equivalents of $34.6 Million reflects Cash Utilization of $1.3 Million in the Second Quarter LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company...
News, Short Squeeze, Breakout and More Instantly...
Total Revenue increased 28% and Procedure volume increased 25% over the first quarter of 2023 Increased ALLY ® Adaptive Cataract Treatment System installed base to 65 systems LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global m...